Abstract Aims Using Scandinavian population-based registries, we assessed risk of
stroke/systemic embolism (SE) and bleeding with non-vitamin K antagonist oral …

Background The nonvitamin K antagonist oral anticoagulants have recently become
available as an alternative to warfarin as stroke prophylaxis in atrial fibrillation, but data on …

Aims The aim of this study was to compare the risk of stroke or systemic embolism (SE) and
major bleeding in patients with atrial fibrillation (AF) using dabigatran, rivaroxaban, and …

Background Stroke is the most serious clinical consequence of atrial fibrillation, which is the
most common cardiac arrhythmia. Non-vitamin K antagonist oral anticoagulants (NOACs) …

Aims Non-vitamin K antagonist oral anticoagulation (NOAC) agents have been approved for
stroke prophylaxis in atrial fibrillation (AF). We investigated 'real-world'information on how …

Objective To study the effectiveness and safety of the non-vitamin K antagonist oral
anticoagulants (novel oral anticoagulants, NOACs) dabigatran, rivaroxaban, and apixaban …

Background and Purpose: The effects of direct oral anticoagulants in nonvalvular atrial
fibrillation should be assessed in actual conditions of use. France has near-universal …

Background Non-vitamin K antagonist (VKA) oral anticoagulants (NOACs) are widely used
as stroke prophylaxis in non-valvular atrial fibrillation (AF), but comparative data are sparse …

Background and Purpose: Several observational studies have compared the effect of the
non–vitamin K antagonist oral anticoagulants to each other in patients with atrial fibrillation …

Vitamin K antagonists (VKAs), together with newer oral anticoagulants (NOACs) such as
dabigatran, rivaroxaban, or apixaban, reduce the risk of stroke in patients with atrial …